{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.90","value":"7.3"},{"groupId":"OG001","spread":"25.25","value":"10.6"}]}],"title":"Loss of appetite (n=403, 197)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.10","value":"10.2"},{"groupId":"OG001","spread":"23.92","value":"10.4"}]}],"title":"Fatigue (n=403, 197)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.09","value":"7.6"},{"groupId":"OG001","spread":"23.81","value":"6.7"}]}],"title":"Cough (n=402, 197)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.50","value":"7.6"},{"groupId":"OG001","spread":"20.44","value":"5.4"}]}],"title":"Dyspnea (n=400, 196)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.96","value":"5.4"},{"groupId":"OG001","spread":"21.93","value":"4.3"}]}],"title":"Pain (n=401, 197)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.41","value":"1.5"},{"groupId":"OG001","spread":"9.23","value":"2.1"}]}],"title":"Hemoptysis (n=402, 196)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.13","value":"6.5"},{"groupId":"OG001","spread":"22.5","value":"8.2"}]}],"title":"Symptom distress (n=401, 196)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.08","value":"10.8"},{"groupId":"OG001","spread":"25.50","value":"9.3"}]}],"title":"Interference with activity level (n=400, 197)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.94","value":"10.7"},{"groupId":"OG001","spread":"22.98","value":"10.5"}]}],"title":"Global quality of life (n=401, 195)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.34","value":"3.7"},{"groupId":"OG001","spread":"13.24","value":"3.8"}]}],"title":"ASBI (n=392, 195)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.76","value":"4.07"},{"groupId":"OG001","spread":"13.03","value":"4.04"}]}],"title":"Total LCSS (n=388, 193)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"403"},{"groupId":"OG001","value":"197"}],"units":"Participants"}],"description":"The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant responses to each item were measured using VAS from 0 (for best outcome) to 100 (for worst outcome). The average symptom burden index (ASBI) was the mean of the 6 symptom-specific items. The LCSS total score was the mean of the 9 items.","dispersionType":"Standard Deviation","groups":[{"description":"Pemetrexed: 500 mg/m\\^2, IV administration, q 21 days, until disease progression.\n\nBSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.","id":"OG000","title":"Pemetrexed and BSC"},{"description":"Placebo: IV administration, q 21 days.\n\nBSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.","id":"OG001","title":"Placebo and BSC"}],"paramType":"MEAN","populationDescription":"Participants who signed the ICF, completed the randomization process, had LCSS data at baseline and at least once postdose are reported according to the treatment arm to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Baseline through 30 days post discontinuation of study treatment (up to 39 Months)","title":"Maximum Improvement Over Baseline in Individual Symptom Scores and Quality of Life Using the LCSS","type":"SECONDARY","unitOfMeasure":"units on a scale"}